The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Use of a navigable interface for integrated whole genome and transcriptome sequencing as a platform for pursuit of therapeutic targets in advanced prostate cancers.
 
Jones T. Nauseef
Consulting or Advisory Role - AIQ Solutions; AIQ Solutions
Travel, Accommodations, Expenses - Digital Science Press
 
Ahmed Elsaeed
No Relationships to Disclose
 
Majd Al Assaad
No Relationships to Disclose
 
Gunes Gundem
Consulting or Advisory Role - Isabl Technologies
 
Max Levine
Employment - Isabl Technologies
Patents, Royalties, Other Intellectual Property - Patents relating to digital biobank and analyzing whole genome sequencing.
 
Jyothi Manohar
No Relationships to Disclose
 
Michael Sigouros
No Relationships to Disclose
 
Brian D. Robinson
Stock and Other Ownership Interests - AstraZeneca
Patents, Royalties, Other Intellectual Property - methods for diagnosing and treating prostate cancer
 
Andrea Sboner
No Relationships to Disclose
 
Juan Medina-Martinez
Employment - Isabl
Leadership - Isabl
Stock and Other Ownership Interests - Isabl
 
Ana M. Molina
Consulting or Advisory Role - Eisai; Eisai; Eisai; Exelixis; Janssen
 
Cora N. Sternberg
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Foundation Medicine; Genzyme; Immunomedics; IMPAC Medical Systems; Incyte; Medscape; Merck; MSD; Pfizer; Roche; UroToday
 
Olivier Elemento
Stock and Other Ownership Interests - OneThree Biotech; Owkin; Volastra Therapeutics
 
Scott T. Tagawa
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Dendreon; Endocyte; Genentech; Genomic Health; Gilead Sciences; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics
 
David M. Nanus
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Exelixis (Inst); immumedics (Inst); Janssen (Inst); Novartis (Inst); pfizer (Inst); Zenith Epigenetics (Inst)
 
Juan Miguel Mosquera
No Relationships to Disclose